|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OTUD7B |
Gene summary for OTUD7B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OTUD7B | Gene ID | 56957 |
| Gene name | OTU deubiquitinase 7B | |
| Gene Alias | CEZANNE | |
| Cytomap | 1q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q6GQQ9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56957 | OTUD7B | CCI_1 | Human | Cervix | CC | 1.71e-13 | 1.57e+00 | 0.528 |
| 56957 | OTUD7B | CCI_2 | Human | Cervix | CC | 1.73e-04 | 5.77e-01 | 0.5249 |
| 56957 | OTUD7B | CCI_3 | Human | Cervix | CC | 2.97e-15 | 9.05e-01 | 0.516 |
| 56957 | OTUD7B | LZE4T | Human | Esophagus | ESCC | 1.55e-11 | 2.68e-01 | 0.0811 |
| 56957 | OTUD7B | LZE5T | Human | Esophagus | ESCC | 2.41e-03 | 2.40e-01 | 0.0514 |
| 56957 | OTUD7B | LZE20T | Human | Esophagus | ESCC | 3.49e-08 | 3.21e-01 | 0.0662 |
| 56957 | OTUD7B | LZE21D1 | Human | Esophagus | HGIN | 6.51e-03 | 2.57e-01 | 0.0632 |
| 56957 | OTUD7B | LZE22T | Human | Esophagus | ESCC | 4.01e-03 | 1.82e-01 | 0.068 |
| 56957 | OTUD7B | LZE24T | Human | Esophagus | ESCC | 2.01e-10 | 2.32e-01 | 0.0596 |
| 56957 | OTUD7B | P1T-E | Human | Esophagus | ESCC | 1.04e-12 | 4.70e-01 | 0.0875 |
| 56957 | OTUD7B | P2T-E | Human | Esophagus | ESCC | 1.35e-14 | 2.63e-01 | 0.1177 |
| 56957 | OTUD7B | P4T-E | Human | Esophagus | ESCC | 4.14e-12 | 1.88e-01 | 0.1323 |
| 56957 | OTUD7B | P5T-E | Human | Esophagus | ESCC | 1.51e-17 | 2.65e-01 | 0.1327 |
| 56957 | OTUD7B | P8T-E | Human | Esophagus | ESCC | 1.59e-20 | 2.00e-01 | 0.0889 |
| 56957 | OTUD7B | P9T-E | Human | Esophagus | ESCC | 5.78e-21 | 3.67e-01 | 0.1131 |
| 56957 | OTUD7B | P10T-E | Human | Esophagus | ESCC | 5.29e-18 | 2.31e-01 | 0.116 |
| 56957 | OTUD7B | P11T-E | Human | Esophagus | ESCC | 1.54e-14 | 4.50e-01 | 0.1426 |
| 56957 | OTUD7B | P12T-E | Human | Esophagus | ESCC | 1.47e-06 | 1.22e-01 | 0.1122 |
| 56957 | OTUD7B | P15T-E | Human | Esophagus | ESCC | 1.87e-18 | 3.70e-01 | 0.1149 |
| 56957 | OTUD7B | P16T-E | Human | Esophagus | ESCC | 7.96e-09 | 1.50e-01 | 0.1153 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
| GO:00431228 | Cervix | CC | regulation of I-kappaB kinase/NF-kappaB signaling | 53/2311 | 249/18723 | 4.50e-05 | 6.87e-04 | 53 |
| GO:00017018 | Cervix | CC | in utero embryonic development | 71/2311 | 367/18723 | 7.21e-05 | 1.00e-03 | 71 |
| GO:00072497 | Cervix | CC | I-kappaB kinase/NF-kappaB signaling | 56/2311 | 281/18723 | 1.81e-04 | 2.12e-03 | 56 |
| GO:19001808 | Cervix | CC | regulation of protein localization to nucleus | 31/2311 | 136/18723 | 4.76e-04 | 4.69e-03 | 31 |
| GO:00711083 | Cervix | CC | protein K48-linked deubiquitination | 10/2311 | 35/18723 | 7.99e-03 | 4.18e-02 | 10 |
| GO:19038286 | Cervix | CC | negative regulation of cellular protein localization | 24/2311 | 117/18723 | 8.10e-03 | 4.23e-02 | 24 |
| GO:003450417 | Esophagus | HGIN | protein localization to nucleus | 84/2587 | 290/18723 | 1.06e-11 | 1.24e-09 | 84 |
| GO:004312220 | Esophagus | HGIN | regulation of I-kappaB kinase/NF-kappaB signaling | 63/2587 | 249/18723 | 8.91e-07 | 3.61e-05 | 63 |
| GO:190018017 | Esophagus | HGIN | regulation of protein localization to nucleus | 40/2587 | 136/18723 | 1.69e-06 | 6.31e-05 | 40 |
| GO:000724918 | Esophagus | HGIN | I-kappaB kinase/NF-kappaB signaling | 67/2587 | 281/18723 | 3.84e-06 | 1.29e-04 | 67 |
| GO:000170118 | Esophagus | HGIN | in utero embryonic development | 77/2587 | 367/18723 | 9.56e-05 | 2.05e-03 | 77 |
| GO:00706463 | Esophagus | HGIN | protein modification by small protein removal | 34/2587 | 157/18723 | 4.68e-03 | 4.02e-02 | 34 |
| GO:003450418 | Esophagus | ESCC | protein localization to nucleus | 211/8552 | 290/18723 | 4.06e-21 | 6.60e-19 | 211 |
| GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
| GO:190018018 | Esophagus | ESCC | regulation of protein localization to nucleus | 102/8552 | 136/18723 | 2.84e-12 | 1.13e-10 | 102 |
| GO:0043122110 | Esophagus | ESCC | regulation of I-kappaB kinase/NF-kappaB signaling | 167/8552 | 249/18723 | 6.11e-12 | 2.32e-10 | 167 |
| GO:000724919 | Esophagus | ESCC | I-kappaB kinase/NF-kappaB signaling | 183/8552 | 281/18723 | 3.02e-11 | 1.01e-09 | 183 |
| GO:19038289 | Esophagus | ESCC | negative regulation of cellular protein localization | 76/8552 | 117/18723 | 1.97e-05 | 1.72e-04 | 76 |
| GO:007064612 | Esophagus | ESCC | protein modification by small protein removal | 95/8552 | 157/18723 | 1.25e-04 | 8.56e-04 | 95 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OTUD7B | SNV | Missense_Mutation | c.751N>A | p.Glu251Lys | p.E251K | Q6GQQ9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A090-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| OTUD7B | SNV | Missense_Mutation | novel | c.1856A>G | p.His619Arg | p.H619R | Q6GQQ9 | protein_coding | tolerated(0.07) | benign(0.347) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OTUD7B | SNV | Missense_Mutation | novel | c.2350N>A | p.Glu784Lys | p.E784K | Q6GQQ9 | protein_coding | tolerated_low_confidence(0.8) | benign(0.105) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| OTUD7B | SNV | Missense_Mutation | c.1870N>G | p.Gln624Glu | p.Q624E | Q6GQQ9 | protein_coding | deleterious(0.01) | benign(0.304) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| OTUD7B | SNV | Missense_Mutation | c.155N>C | p.Leu52Pro | p.L52P | Q6GQQ9 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| OTUD7B | SNV | Missense_Mutation | c.524N>A | p.Ser175Asn | p.S175N | Q6GQQ9 | protein_coding | tolerated(0.53) | benign(0) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD | |
| OTUD7B | SNV | Missense_Mutation | c.293N>T | p.Gly98Val | p.G98V | Q6GQQ9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A155-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| OTUD7B | SNV | Missense_Mutation | c.170G>T | p.Ser57Ile | p.S57I | Q6GQQ9 | protein_coding | deleterious(0.01) | benign(0.147) | TCGA-E9-A1RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
| OTUD7B | SNV | Missense_Mutation | novel | c.344C>T | p.Ser115Phe | p.S115F | Q6GQQ9 | protein_coding | tolerated(0.06) | probably_damaging(0.929) | TCGA-EW-A1PE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| OTUD7B | SNV | Missense_Mutation | novel | c.1554N>C | p.Lys518Asn | p.K518N | Q6GQQ9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-LQ-A4E4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |